SSA
XLRN

Schonfeld Strategic Advisors’s Acceleron Pharma XLRN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,807
Closed -$1.34M – 2826
2021
Q3 		$1.34M Sell
7,807
-8,561
-52% -$1.12M 0.01% 848
2021
Q2 		$2.05M Buy
16,368
+8,068
+97% +$1.02M 0.02% 701
2021
Q1 		$1.13M Buy
8,300
+3,200
+63% +$413K 0.01% 844
2020
Q4 		$653K Buy
+5,100
New +$598K 0.01% 952
2020
Q3 		– Sell
-10,726
Closed -$1.02M – 1781
2020
Q2 		$1.02M Buy
+10,726
New +$1.03M 0.03% 594
2020
Q1 		– Sell
-28,611
Closed -$1.52M – 1662
2019
Q4 		$1.52M Buy
28,611
+411
+1% +$18.7K 0.04% 394
2019
Q3 		$1.11M Buy
+28,200
New +$1.22M 0.03% 447
2017
Q4 		– Sell
-144,017
Closed -$5.38M – 941
2017
Q3 		$5.38M Buy
+144,017
New +$5M 0.49% 60
2017
Q2 		– Sell
-9,419
Closed -$250K – 834
2017
Q1 		$250K Buy
+9,419
New +$248K 0.03% 504

Schonfeld Strategic Advisors's XLRN Position: Q4 2021 in Review

Schonfeld Strategic Advisors sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 7,807 shares — an estimated $1.34M sold.

Schonfeld Strategic Advisors first reported a position in XLRN in Q1 2017 and held it in 9 quarters. The position peaked at $5.38M in Q3 2017. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Schonfeld Strategic Advisors reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 7,807 Acceleron Pharma shares in Q4 2021, an estimated $1.34M.
  • Schonfeld Strategic Advisors first reported a position in Acceleron Pharma in Q1 2017 and held it in 9 quarters.
  • Schonfeld Strategic Advisors's Acceleron Pharma position peaked at $5.38M in Q3 2017.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.